Search Result

Results for "

CDK+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (18) Autophagy (4) Bcl-2 Family (1) Caspase (2) CDK (76) CFTR (1) COX (1) Cytochrome P450 (1) DNA/RNA Synthesis (1) Drug Intermediate (1) Drug-Linker Conjugates for ADC (1) EGFR (1) ERK (2) Flavivirus (1) GSK-3 (9) Guanylate Cyclase (2) HIV (2) JAK (2) JNK (1) Ligands for Target Protein for PROTAC (5) MEK (2) Molecular Glues (1) PKC (1) PROTACs (1) Reference Standards (5) Src (1) VEGFR (1)
By Research Areas:	Cancer (69) Cardiovascular Disease (3) Endocrinology (1) Infection (3) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (5)

By Targets:

Apoptosis (18)

Autophagy (4)

Bcl-2 Family (1)

Caspase (2)

CDK (76)

CFTR (1)

COX (1)

Cytochrome P450 (1)

DNA/RNA Synthesis (1)

Drug Intermediate (1)

Drug-Linker Conjugates for ADC (1)

EGFR (1)

ERK (2)

Flavivirus (1)

GSK-3 (9)

Guanylate Cyclase (2)

HIV (2)

JAK (2)

JNK (1)

Ligands for Target Protein for PROTAC (5)

MEK (2)

Molecular Glues (1)

PKC (1)

PROTACs (1)

Reference Standards (5)

Src (1)

VEGFR (1)

By Research Areas:

Cancer (69)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (3)

Metabolic Disease (2)

Neurological Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10005

Flavopiridol Maximum Cited Publications 52 Publications Verification HMR-1275; Alvocidib; L86-8275	CDK Autophagy HIV Apoptosis	Cancer
Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of *CDKs*, inhibiting CDK1, CDK2, CDK4 with IC₅₀s of 30, 170, 100 nM, respectively.

HY-30237

(R)-Roscovitine 30+ Cited Publications Seliciclib; CYC202	CDK	Neurological Disease Metabolic Disease Cancer
(R)-Roscovitine (Seliciclib) is an orally bioavailable, selective and BBB-permeable *CDKs* inhibitor with IC₅₀s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.

HY-13914

Roniciclib 2 Publications Verification BAY 1000394	CDK	Cancer
Roniciclib is an orally bioavailable pan-cyclin dependent kinase *(CDK)* inhibitor, with IC₅₀s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.

HY-12422

Voruciclib	CDK	Cancer
Voruciclib is an orally active and selective *CDK* inhibitor with K_i values of 0.626 nM-9.1 nM. Voruciclib potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL) .

HY-130709

PROTAC CDK2/9 Degrader-1	PROTACs CDK	Cancer
PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC₅₀=62 nM) and CDK9 (DC₅₀=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC₅₀=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering *CDK* inhibitor with Cereblon ligand .

HY-11001

PHA-793887 4 Publications Verification	CDK Apoptosis	Cancer
PHA-793887 is a potent, ATP-competitive *CDK* inhibitor, can inhibit Cdk2, Cdk1, Cdk4, and Cdk9 with IC₅₀s of 8 nM, 60 nM, 62 nM and 138 nM, respectively, and also inhibits glycogen synthase kinase 3β with an IC₅₀ of 79 nM.

HY-10014

R547 2 Publications Verification	CDK GSK-3 Apoptosis	Cancer
R547 is a potent, selective and orally active ATP-competitive *CDK* inhibitor, with K_is of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively .

HY-18299A

Purvalanol A 4 Publications Verification NG-60	CDK Autophagy Apoptosis	Cancer
Purvalanol A is a potent *CDK* inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC₅₀s of 4, 70, 35, 850, 75 nM, resepctively.

HY-15504A

RGB-286638 free base 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a *CDK* inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-108359

Alsterpaullone 1 Publications Verification 9-Nitropaullone; NSC 705701	CDK GSK-3 Apoptosis	Cancer
Alsterpaullone (9-Nitropaullone) is a potent *CDK* inhibitor, with IC₅₀s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC₅₀s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders . Alsterpaullone induces apoptosis in leukemia cell line .

HY-78428

CDK-IN-6	CDK	Cancer
CDK-IN-6, a class of pyrazolo[1,5-a]pyrimidine compound, is a *CDK* inhibitor with anticancer activities .

HY-15491

AG-024322	COX Apoptosis	Cancer
AG-024322 is a potent ATP-competitive pan-CDK* inhibitor* against cell cycle kinases CDK1, CDK2, and CDK4 with K_i values in the 1-3 nM range . AG-024322 displays broad-spectrum anti-tumor activity and clear target modulation in vivo. AG-024322 induces cell apoptosis .

HY-11009

CGP60474 5+ Cited Publications	CDK PKC	Cancer
CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC₅₀ values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor .

HY-15504

RGB-286638 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a *CDK* inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-13033

CDK-IN-2 1 Publications Verification CDK inhibitor II	CDK	Endocrinology
CDK-IN-2 is a specific CDK9 inhibitor with an IC₅₀ of less than 8 nM. CDK-IN-2 reduces the phosphorylation level of H3S10. CDK-IN-2 decreases the transition rate of spermatocytes from prophase to metaphase I .

HY-126534A

Abemaciclib metabolite M18 hydrochloride 2 Publications Verification LSN3106729 hydrochloride	Ligands for Target Protein for PROTAC CDK	Cancer
Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a *CDK* inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .

HY-16559

Riviciclib hydrochloride 3 Publications Verification P276-00	CDK Apoptosis	Cancer
Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .

HY-114779

N9-Isopropylolomoucine	CDK	Cancer
N9-Isopropylolomoucine is a mitotic cyclin dependent kinase (CDK) inhibitor. N9-Isopropylolomoucine targets CCNB 1/CDK1 and can be used for cancer research .

HY-126534

Abemaciclib metabolite M18 2 Publications Verification LSN3106729	Ligands for Target Protein for PROTAC CDK	Cancer
Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a *CDK* inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .

HY-W013386

LY83583 1 Publications Verification	Guanylate Cyclase	Cardiovascular Disease Neurological Disease Cancer
LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease .

HY-151071

TMX-3013	Ligands for Target Protein for PROTAC CDK	Cancer
TMX-3013 is a *CDK* inhibitor capable of inhibiting the activity of CDK1, CDK2, CDK4, CDK5, and CDK6, with IC₅₀ values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM, respectively. TMX-3013 can be used as a target protein ligand, conjugated with the PROTAC linker and the CRBN ligand Thalidomide (HY-14658) for the synthesis of PROTAC TMX-2138 (HY-164906). TMX-3013 can also act as an effector ligand, binding to target proteins HaloTag or FKBP, and can be used in the synthesis of regulated induced proximity targeting chimeras (RIPTACs) .

HY-W077292

2,4,6-Trihydroxybenzoic acid	CDK	Cancer
2,4,6-Trihydroxybenzoic acid, the flavonoid metabolite, is a *CDK* inhibitor. 2,4,6-Trihydroxybenzoic acid can be used for the research of cancer .

HY-155805

SGC-CAF382-1	CDK	Cancer
CAF-382 (compound B1) is an analog of SNS-032 and a CDKL5 and pan-CDK inhibitor with a weak GSK3α/β affinity (>1.8 μM) and inhibitory activity. CAF-382 inhibits CDKL5 and blocks the phosphorylation of the CDKL5 E2 domain .

HY-14372

BS-194	CDK	Cancer
BS-194 is an orally active, selective and potent *CDK* inhibitor. BS-194 inhibits CDK2, CDK1, CDK5, CDK7, CDK9 (IC₅₀s: 3, 30, 30, 250, and 90 nM respectively). BS-194 potently inhibits cancer cells proliferation. BS-194 can be used in the research of cancers like breast cancer, colon cancer .

HY-119715

AG-012986	CDK Apoptosis	Inflammation/Immunology Cancer
AG-012986 is a pan-CDK* inhibitor* with K_i values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces K_i-67 expression. AG-012986 exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .

HY-145599

Tanuxiciclib	CDK	Cancer
Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor .

HY-145563

Eciruciclib	CDK	Cancer
Eciruciclib is an antineoplastic and potent cyclin dependent kinase (CDK) inhibitor .

HY-W007367

2,6-Dichloropurine	Drug Intermediate	Others
2,6-Dichloropurine is a pharmaceutical intermediate. 2,6-Dichloropurine can be used to synthesize various PDE inhibitors, human A3 adenosine receptor (AR) antagonists, and CDK inhibitors .

HY-19316

NU2058 O6-(Cyclohexylmethyl)guanine	CDK	Cancer
NU2058 (O6-(Cyclohexylmethyl)guanine) is a potent, competitive and guanine-based *CDK* inhibitor with IC₅₀s of 17 μM and 26 μM for CDK2 and CDK1. NU2058 has anti-cancer activity.

HY-12422A

Voruciclib hydrochloride	CDK	Cancer
Voruciclib hydrochloride is an orally active and selective *CDK* inhibitor with K_i values of 0.626 nM-9.1 nM. Voruciclib hydrochloride potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib hydrochloride represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL) .

HY-151069

TMX-2039	Ligands for Target Protein for PROTAC CDK	Cancer
TMX-2039 is a *pan-CDK* inhibitor for both cell cycle CDKs (CDK1, CDK2, CDK4, CDK5 and CDK6) and transcriptional CDKs (CDK7 and CDK9), with IC₅₀s of 2.6, 1.0, 52.1, 0.5, 35.0, 32.5 and 25 nM, respectively. TMX-2039 acts as a Ligands for Target Protein for PROTACs .

HY-153336

PRT3645	CDK	Cancer
PRT3645 (Example 20) is a CDK Inhibitor. CDK-IN-12 Inhibits CDK4/6 with IC₅₀ values less than 20 nM .

HY-112403

(S)-Roscovitine 1 Publications Verification (S)-Seliciclib; (S)-CYC202	CDK	Neurological Disease
(S)-Roscovitine ((S)-Seliciclib; (S)-CYC202) is a potent and cross the blood-brain barrier *CDKs* inhibitor. (S)-Roscovitine shows neuroprotective efficacy. (S)-Roscovitine has the potential for the research of stroke .

HY-151898

CDK4/6-IN-14	CDK	Cancer
CDK4/6-IN-14 is a potent and highly selective CDK4 and CDK6 (CDK) inhibitor with IC₅₀s of 10 nM and 16 nM, respectively. CDK4/6-IN-14 exhibits more than 60-fold selectivity over CDKs 1, 2, 7, and 9, and shows high selectivity among other 205 kinases .

HY-156643

Tacaciclib	CDK	Cancer
Tacaciclib is a CDK inhibitor, antineoplastic effect .

HY-12422B

(2S,3R)-Voruciclib hydrochloride	CDK	Cancer
(2S,3R)-Voruciclib hydrochloride is the enantiomer of Voruciclib hydrochloride. Voruciclib is an orally active *CDK* inhibitor.

HY-W077292R

2,4,6-Trihydroxybenzoic acid (Standard)	Reference Standards CDK	Cancer
2,4,6-Trihydroxybenzoic acid, the flavonoid metabolite, is a CDK inhibitor. 2,4,6-Trihydroxybenzoic acid can be used for the research of cancer .

HY-111356

IIIM-290	CDK	Cancer
IIIM-290 is a potent and oral *CDK* inhibitor with IC₅₀s of 90 and 94 nM for CDK2/A and CDK9/T1.

HY-150641

CDK-IN-9	CDK Apoptosis DNA/RNA Synthesis Molecular Glues	Cancer
CDK-IN-9 (compound 24) is a potent *CDK* inhibitor, also as a molecular glue inducing an interaction between CDK12 and DDB1, with an IC₅₀ values of 4 nM for CDK2/E. CDK-IN-9 leads to polyubiquitination of cyclin K and its subsequent degradation. CDK-IN-9 induce apoptosis through dephosphorylation of retinoblastoma protein and RNA polymerase II .

HY-16559A

Riviciclib P276-00 free base	CDK	Cancer
Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib shows antitumor activity on cisplatin-resistant cells .

HY-151878

CDK7-IN-20	CDK GSK-3	Metabolic Disease
CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC₅₀ value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research .

HY-112450

Olomoucine II	CDK	Cancer
Olomoucine II is a potent *CDK* inhibitor with IC₅₀ values of 0.06, 0.1, 0.45, 7.6, 19.8 µM for CDK9/cyclin T, CDK2/cyclin E, CDK7/cyclin H, CDK1/cyclin B, CDK4/cyclin D1, respectively. Olomoucine II shows antiproliferative activity .

HY-12843

Bohemine 1 Publications Verification	CDK ERK	Cancer
Bohemine is a purine analogue and is a synthetic and selective *CDK* inhibitor with IC₅₀s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC₅₀ of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities .

HY-112371

(S)-CR8	CDK	Cancer
(S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective *CDK* inhibitor with IC₅₀s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC₅₀ 0.40 μM) .

HY-112363

Aloisine A RP107	CDK GSK-3 ERK JNK CFTR	Inflammation/Immunology Cancer
Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC₅₀s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC₅₀=0.5 μM) and GSK-3β (IC₅₀=1.5 μM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research .

HY-147386

CDK-IN-10	CDK	Cancer
CDK-IN-10 (example 54) is a cyclin dependent kinase (CDK) inhibitor that can be used in cancer research .

HY-114248

AGM-130	CDK	Cancer
AGM-130 is a cyclin-dependent kinase (CDK) inhibitor. AGM-130 exhibits antitumor activity .

HY-P11013

p27	CDK	Cancer
p27, a *CDK* inhibitor, is a SCFSkp2/Cks1 substrate. p27 can be used for the study of cancer .

HY-162785

XC219	CDK	Infection
XC219 (compound 43) is a cyclin-dependent kinase *CDK*) inhibitor, that covalently binds to CDK active site Lys. XC219 can be used in antifungal research .

HY-137062

CGP-79807	CDK	Cancer
CGP-79807 is a purine-based *CDK* inhibitor. CGP-79807 can block the cell cycle by inhibiting CDK activity to suppress the proliferation of tumor cells. CGP-79807 can be used in the study of cancer .

Cat. No.	Product Name	Target	Research Area

HY-P11013

p27	CDK	Cancer
p27, a *CDK* inhibitor, is a SCFSkp2/Cks1 substrate. p27 can be used for the study of cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W077292

2,4,6-Trihydroxybenzoic acid	Classification of Application Fields Ketones, Aldehydes, Acids Phenols Polyphenols Endogenous metabolite Disease Research Fields Source Classification Cancer	CDK
2,4,6-Trihydroxybenzoic acid, the flavonoid metabolite, is a *CDK* inhibitor. 2,4,6-Trihydroxybenzoic acid can be used for the research of cancer .

HY-W077292R

2,4,6-Trihydroxybenzoic acid (Standard)	Ketones, Aldehydes, Acids Phenols Polyphenols Endogenous metabolite Source Classification	Reference Standards CDK
2,4,6-Trihydroxybenzoic acid, the flavonoid metabolite, is a CDK inhibitor. 2,4,6-Trihydroxybenzoic acid can be used for the research of cancer .

HY-N12625A

(S)-(-)-O-Demethylbuchenavianine	Alkaloids Flavonoids Flavones Other Alkaloids Buchenavia macrophylla Spruce ex Eichler Combretaceae Plants Source Classification	CDK
(S)-(-)-O-Demethylbuchenavianine (Compound (S)-(−)-1) is a flavonoidal alkaloids. (S)-(-)-O-Demethylbuchenavianine is a potent *CDK* inhibitor, with IC₅₀ values of 0.03 and 0.05 μM for CDK1 and CDK5, respectively .

Cat. No.	Product Name	Chemical Structure

HY-126534S

Abemaciclib metabolite M18-d8
Abemaciclib metabolite M18-d₈ is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks